



ASX / MEDIA RELEASE

ResApp Receives Notice of Allowance for Core Patent in US

Brisbane, Australia, 6 June 2018 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application 14/389,291 titled "Method and Apparatus for Processing Patient Sounds" covering the use of a cough sound based audio processing pipeline for diagnosing respiratory disease. This patent protects a key component of ResAppDx, ResApp's smartphone application for diagnosing acute respiratory disease.

Tony Keating, CEO and Managing Director of ResApp commented, "Securing a strong patent position in the United States is an important milestone for the company. In alignment with our IP protection strategy, having a comprehensive patent portfolio in place is a key component as we work expediently towards regulatory approval and market entry."

The patent is owned by The University of Queensland and is licensed exclusively to ResApp for the lifetime of the patent. The inventors are Dr Udantha Abeyratne, Chief Scientist and scientific co-founder of ResApp, Dr Vinayak Swarnkar and Dr Yusuf Amrulloh. ResApp has patent applications covering similar subject matter pending in Europe, Australia, Japan, China and South Korea. ResApp has also filed, or has exclusive license to three other patent applications which are at either provisional or Patent Cooperation Treaty (PCT) application stage.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Adult and paediatric clinical studies underway at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.

In the United States, ResAppDx is an investigational device and is not available for sale.

For more information on ResApp, visit www.resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E info@resapphealth.com.au W www.resapphealth.com.au



Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au